# Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

> **NCT05018806** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 124 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Rilzabrutinib

## Key facts

- **NCT ID:** NCT05018806
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-09
- **Primary completion:** 2023-06-23
- **Final completion:** 2023-06-23
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05018806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05018806, "Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05018806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*